Area of research
Immunology and Allergy · Physiology
Research interest
Research interests include Allergic Rhinitis and Sensitization, Asthma and respiratory diseases, Sinusitis and nasal conditions, and Nasal Surgery and Airway Studies.
Real-World Effectiveness of Mepolizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps: Findings From the European CRS Outcome Registry (CHRINOSOR).
Interaction between airway basal cells, mast cells and type 2 immunity contributes to epithelial barrier dysfunction in allergic rhinitis.
Corrigendum to "The EUFOREA pocket guide on paediatric asthma: A step forward in patient care" [Respir. Med. (2025) 108631].
A patient-centric approach to chronic rhinosinusitis with nasal polyps (CRSwNP): developing tools to improve disease management and outcomes.
Indication for biologic treatment in a real-world cohort of chronic rhinosinusitis patients according to international recommendations: Evidence from the European CRS outcome registry (CHRINOSOR).
EUFOREA summit in Brussels 2025: inspiring the future of allergy and respiratory care.
Shaping the Future of Respiratory Care: A Look Into the Next Decade and Strategic Recommendations by the European Forum for Research and Education in Allergy and Airways Diseases.
The EUFOREA pocket guide on paediatric asthma: A step forward in patient care.
Meta-Analysis on the Harm of Systemic Glucocorticosteroids in Inflammatory Upper Airway Disease and Asthma: An EAACI Task Force.
Promoting Prevention and Targeting Remission of Asthma: A EUFOREA Consensus Statement on Raising the Bar in Asthma Care.
Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial.
Remission in chronic rhinosinusitis with nasal polyps (CRSwNP).
Pocket guide: biologics in upper and lower airways in adults.
Chronic rhinosinusitis with nasal polyps: Key considerations in the multidisciplinary team approach.
Characterization of Chronic Rhinosinusitis Patients Based on Markers of Type 2 Inflammation: Findings From the European CRS Outcome Registry (CHRINOSOR).
Clinical management of dupilumab-induced blood eosinophilia in CRSwNP: a practical algorithm.
Global airway disease: mepolizumab simultaneously improves outcomes in severe CRSwNP and asthma.
Effect of biological treatment in uncontrolled severe chronic rhinosinusitis with nasal polyps in Belgium: a multicentre real-world data study.
Radiological score, asthma and NSAID-exacerbated respiratory disease predict relapsing chronic rhinosinusitis.
Algorithm for the Management of Primary Diffuse Chronic Rhinosinusitis.
A RESPONSE to anti<b>-</b>IL-5 therapy in comorbid patients with chronic rhinosinusitis with nasal polyps and severe asthma: Study protocol.
Real-life evaluation of the effectiveness of biologics for chronic rhinosinusitis with nasal polyps in Europe: a Delphi study to define key variables for the INVENT registry.
Validation of the Skin Prick Automated Test (SPAT) Cut-Off Value in Birch Pollen and House Dust Mite Allergic Rhinitis Patients.
Raising the bar in respiratory care by EUFOREA: report of the European Union Parliament Symposium, April 2024
Impact of biologicals on revision ESS numbers in CRSwNP in a tertiary care rhinology center.
Rhino(septo)plasty Informed Consent. Consensus by the European Rhinoplasty Course Faculty-EUFOREA.
Indication for biologics in a real-world cohort of dupilumab treated chronic rhinosinusitis with nasal polyps patients according to international recommendations: evidence from the European CRS Outcome Registry (CHRINOSOR).
Raising the bar in respiratory care by EUFOREA: report of the European Union Parliament Symposium, April 2024.
ULANC - EUFOREA workshop 2024: bringing the concept of global airways to the frontline of medical care.
Mouse model of Staphylococcus aureus- and Pseudomonas aeruginosa-induced neutrophilic chronic rhinosinusitis.